FDA Discusses Authorization Approaches Regarding COVID-19 Vaccines for Children
The U.S. Food and Drug Administration (FDA) Center for Biologics Evaluation and Research is conducting a virtual meeting of the 15 voting members of the Vaccines and Related Biological Products Advisory Committee (VRBPAC) on June 10, 2021.
During the meeting, the FDA will provide a status update on its risk-benefit approach to issuing emergency use authorization (EUA) for experimental COVID-19 vaccines intended for use in individuals 12 through 17 years of age.
Furthermore, the VRBPAC committee will discuss the data needed to support a EUA and a biologics license application (BLA) for a COVID-19 vaccine intended for use in children older than six months of age.
The FDA committee will not discuss any specific products during this open meeting. Materials for this meeting will be available on the Vaccines and Related Biological Products Advisory Committee meeting's page.
The meeting is broadcast on Youtube.